PubMed Health⌕ Search

PubMed · 12236369

A microscale-molecular weight sensor: probing molecular diffusion between adjacent laminar flows by refractive index gradient detection.

Abstract

A detection scheme that measures the refractive index gradient (RIG) between adjacent laminar flows in a microfluidic device has been used to develop a microscale-molecular weight sensor. The behavior of low Reynolds number flows has been well documented and shows that molecular transport (mixing) between adjacent laminar flows occurs by molecular diffusion between flow boundaries. A diode laser beam, incident upon and illuminating the entire width of a microchannel, measured the transverse concentration gradient at two different positions along a microchannel. The concentration gradient is impacted by the transverse diffusion from a flow with analyte into a flow initially without analyte. The RIG that forms as analyte diffuses from one adjacent flow to the other causes the laser beam, impinging orthogonal to the RIG through the microchannel, to be deflected. The angle of deflection is then monitored on a position-sensitive detector (PSD) at two different positions along the axis of flow to provide a measurement of analyte diffusion. The two positions are just after the flow initially without analyte merges with the flow initially containing all of the analyte (upstream) and then after the two streams have had more time to diffuse together (downstream). The ratio of the PSD signals obtained at the two positions along the flow, downstream signal divided by the upstream signal, is readily correlated to the analyte diffusion coefficient and, thus, the analyte molecular weight for a given class of compounds. The device was evaluated as a molecular weight sensor for poly(ethylene glycol) (PEG) solutions over a molar mass range from 106 to 22,800 g/mol. The ratio signal was found to be both independent of PEG concentration and sensitive to molecular weight changes for samples ranging from 960 to 22,800 g/mol. Independence of concentration is important for obtaining a reliable molecular weight measurement. The limit of detection for 11,840 g/mol PEG measured at the upstream detection position was determined to be 56 ppm, equivalent to 4.5 x 10(-6) RI (3sigma). This technique provides a much needed universal detection method, without requiring analyte derivatization chemistry (e.g., fluorescence), for microfluidic analyses that are becoming increasingly useful in monitoring chemical systems such as continuous-flow reactors or batch polymerization processes. Thus, the molecular weight determination capability is potentially applicable to other compound classes, such as DNA or proteins.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Colin D Costin, Robert E Synovec. 2002-09-01. A microscale-molecular weight sensor: probing molecular diffusion between adjacent laminar flows by refractive index gradient detection.. https://doi.org/10.1021/ac020143z

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗